The 3-month review extension allows the agency time to assess updated liver safety data and determine whether a REMS program ...
The expanded indication provides a provider-administered IL-23 inhibitor option for adult patients with or without prior anti-TNF exposure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results